Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer Chemotherapy and Pharmacology
Published in: Cancer Chemotherapy and Pharmacology 1/2009

01-12-2009 | Short Communication

The polyamine analog PG11047 potentiates the antitumor activity of cisplatin and bevacizumab in preclinical models of lung and prostate cancer

Authors: K. Dredge, J. A. Kink, R. M. Johnson, I. Bytheway, L. J. Marton

Published in: Cancer Chemotherapy and Pharmacology | Issue 1/2009

Login to get access

Abstract

Purpose

PG11047 is a polyamine analog currently in Phase I trials for advanced cancer as a monotherapy and in combination with a number of approved anti-cancer agents. The use of polyamines as a target for antiproliferative therapy is based on findings that cells synthesize polyamines excessively when induced to grow and that polyamine metabolism is frequently dysregulated in cancer. A selective polyamine transport system provides access for PG11047 into rapidly dividing cells to inhibit polyamine biosynthetic enzymes, to induce the polyamine catabolic enzymes spermidine/spermine N 1-acetyltransferase (SSAT) and spermine oxidase (SMO) which could subsequently induce reactive oxygen species that contribute to tumor cell responses to PG11047, and to function as a polyamine with altered function when it binds to natural polyamine binding sites. The objective of the present study was to assess the antitumor effects of PG11047 alone and in combination with approved anti-cancer agents.

Methods

The antitumor efficacy of PG11047 as a single agent, and in combination with cisplatin and bevacizumab, was tested in models of lung (A549) and prostate (DU-145) cancer, respectively.

Results

PG11047 significantly inhibited tumor development in both lung and prostate cancer models when administered as a single agent. In the lung cancer model, PG11047 potentiated the antitumor effect of cisplatin. Although potent activity was observed with PG11047 and bevacizumab when administered as single agents in the prostate cancer model, the combination arm significantly enhanced antitumor activity compared with either agent alone. In all experiments, PG11047 was well tolerated with no adverse effects on bodyweight gain.

Conclusions

The preclinical data support the rationale for the current Phase I trials which are assessing PG11047 as a monotherapy and in combination with a number of approved anti-cancer agents including cisplatin and bevacizumab.
Literature
1.
Heby O (1981) Role of polyamines in the control of cell proliferation and differentiation. Differentiation 19:1–20PubMedCrossRef
2.
Janne J, Alhonen L, Leinonen P (1991) Polyamines: from molecular biology to clinical applications. Ann Med 23:241–259PubMedCrossRef
3.
4.
Igarashi K, Kashiwagi K (2000) Polyamines: mysterious modulators of cellular functions. Biochem Biophys Res Commun 271:559–564PubMedCrossRef
5.
Matsufuji S, Matsufuji T, Miyazaki Y et al (1995) Autoregulatory frameshifting in decoding mammalian ornithine decarboxylase antizyme. Cell 80:51–60PubMedCrossRef
6.
Casero RA Jr, Marton LJ (2007) Targeting polyamine metabolism and function in cancer and other hyperproliferative diseases. Nat Rev Drug Discov 6:373–390PubMedCrossRef
7.
Seiler N (2005) Pharmacological aspects of cytotoxic polyamine analogs and derivatives for cancer therapy. Pharmacol Ther 107:99–119PubMedCrossRef
8.
Reddy VK, Valasinas A, Sarkar A et al (1998) Conformationally restricted analogues of 1N, 12N-bisethylspermine: synthesis and growth inhibitory effects on human tumor cell lines. J Med Chem 41:4723–4732PubMedCrossRef
9.
Valasinas A, Sarkar A, Reddy VK et al (2001) Conformationally restricted analogues of 1N, 14N-bisethylhomospermine (BE-4–4-4): synthesis and growth inhibitory effects on human prostate cancer cells. J Med Chem 44:390–403PubMedCrossRef
10.
Huang Y, Pledgie A, Casero RA et al (2005) Molecular mechanisms of polyamine analogs in cancer cells. Anticancer Drugs 16:229–241PubMedCrossRef
11.
Holst CM, Frydman B, Marton LJ, Oredsson SM (2006) Differential polyamine analogue effects in four human breast cancer cell lines. Toxicology 223:71–81PubMedCrossRef
12.
Hacker A, Marton LJ, Sobolewski M, Casero RA Jr (2008) In vitro and in vivo effects of the conformationally restricted polyamine analogue CGC-11047 on small cell and non-small cell lung cancer cells. Cancer Chemother Pharmacol 63(1):45–53PubMedCrossRef
13.
Mitchell JL, Thane TK, Sequeira JM et al (2007) Antizyme and antizyme inhibitor activities influence cellular responses to polyamine analogs. Amino Acids 33:291–297PubMedCrossRef
14.
Ha HC, Woster PM, Yager JD et al (1997) The role of polyamine catabolism in polyamine analogue-induced programmed cell death. Proc Natl Acad Sci USA 94:11557–11662PubMedCrossRef
15.
Wang Y, Devereux W, Woster PM (2001) Cloning and characterization of a human polyamine oxidase that is inducible by polyamine analogue exposure. Cancer Res 61:5370–5373PubMed
16.
Wang Y, Murray-Stewart T, Devereux W (2003) Properties of purified recombinant human polyamine oxidase PAOh/SMO. Biochem Biophys Res Commun 304:605–611PubMedCrossRef
17.
Devereux W, Wang Y, Stewart TM (2003) Induction of the PAOh1/SMO polyamine oxidase by polyamine analogues in human lung carcinoma cells. Cancer Chemother Pharmacol 52(5):383–390PubMedCrossRef
18.
Hawthorn TR, Austin JK Jr (1996) Synergism of the polyamine analogue, N1, N11-bisethylnorspermine with cis-diaminedichloroplatinum (II) against murine neoplastic cell lines in vitro and in vivo. Cancer Lett 99(1):99–107CrossRef
19.
Svensson KJ, Welch JE, Kucharzewska P (2008) Hypoxia-mediated induction of the polyamine system provides opportunities for tumor growth inhibition by combined targeting of vascular endothelial growth factor and ornithine decarboxylase. Cancer Res 68(22):9291–9301PubMedCrossRef
20.
21.
Liang WC, Wu X, Peale FV et al (2006) Cross-species vascular endothelial growth factor (VEGF)-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF. J Biol Chem 281(2):951–961PubMedCrossRef
22.
Allen WL, McLean EG, Boyer J et al (2007) The role of spemidine/spermine N1-acetyltransferase in determining response to chemotherapeutic agents in colorectal cancer cells. Mol Cancer Ther 6(1):128–137PubMedCrossRef
23.
Varma R, Hector S, Greco WR et al (2007) Platinum drug effects on the expression of genes in the polyamine pathway: time-course and concentration-effect analysis based on Affymetrix gene expression profiling of A2780 ovarian carcinoma cells. Cancer Chemother Pharmacol 59:711–723PubMedCrossRef
24.
Morrison RF, Seidel ER (1995) Vascular endothelial cell proliferation: regulation of cellular polyamines. Cardiovasc Res 29:841–847PubMed
25.
Carew JS, Nawrocki ST, Reddy VK et al (2008) The novel polyamine analogue CGC-11093 enhances the antimyeloma activity of bortezomib. Cancer Res 68:4783–4790PubMedCrossRef
Metadata
Title
The polyamine analog PG11047 potentiates the antitumor activity of cisplatin and bevacizumab in preclinical models of lung and prostate cancer
Authors
K. Dredge
J. A. Kink
R. M. Johnson
I. Bytheway
L. J. Marton
Publication date
01-12-2009
Publisher
Springer-Verlag
Published in
Cancer Chemotherapy and Pharmacology / Issue 1/2009
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-009-1105-7

Other articles of this Issue 1/2009

Cancer Chemotherapy and Pharmacology 1/2009 Go to the issue

Original Article

A dose-finding and pharmacokinetic study of nedaplatin in elderly patients with advanced non-small cell lung cancer

Original Article

Combination analyses of anti-cancer drugs on human neuroendocrine tumor cell lines

Mini Review

UGT1A1 polymorphism and hyperbilirubinemia in a patient who received sorafenib

Short Communication

Hepatic portal venous gas in a patient with metastatic non-small cell lung cancer on bevacizumab therapy: a case report and review of the literature

Original Article

Biological reactive intermediates that mediate dacarbazine cytotoxicity

Original Article

A dose escalation and pharmacokinetic study of the biweekly administration of paclitaxel, gemcitabine and oxaliplatin in patients with advanced solid tumors
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits